Diligence memo · auto-generated · as of July 2, 2026
Abbott Laboratories
Abbott Laboratories looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Abbott Laboratories operates in Pharmaceuticals, based in Abbott Park.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Abbott Laboratories has raised $6.8M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.7M on 2009-03-02.
Most recent recorded round closed around 2011-03-01.
Valuation (modeled)modeled
Provath models Abbott Laboratories at approximately $3.1M (range $115K–$17M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.02× the median modeled value of Series A Pharmaceuticals companies in 2010–2012 (57 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 24 months.
Last raise 15.3 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 66.9× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 48% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 6% of those peers.
Closest niche peers: Satori Pharmaceuticals Inc, Labrys Biologics, Inc., Telsar Pharma, Inc., Acetylon Pharmaceuticals, Inc., Seldar Pharma, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.